Secondary endpoints
low disease activity
REMISSION, DISEASE
The ACR50 response rate at week 12 was 33.3% in the TAS5315 combined group and 13.3% with placebo (p=0.072; In the PPS, both Simple Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) scores improved over time up to week 12 in the TAS5315 groups to a greater extent than with placebo (Secondary endpoints at week 12. Proportion of patients meeting (A) Simple Disease Activity Index (SDAI), (B) Clinical Disease Activity Index (CDAI) and (C) Disease Activity Score 28-high sensitivity C reactive protein (DAS28-hSCRP) thresholds for low disease activity or remission, and (D) mean change in Health Assessment Questionnaire-Disability Index (HAQ-DI) score. *p<0.05 vs placebo,**p<0.01 vs placebo.Similarly, DAS28 based on hsCRP levels (DAS28-hsCRP) decreased (improved) over time up to week 12 in all treatment groups. The mean percentage change from baseline to week 12 was similar in the TAS5315 groups, and was greater than in the placebo group (HAQ-DI scores improved over time in all treatment groups, but the magnitude of the change was significantly greater at week 12 in the TAS5315 combined group than the placebo group (p<0.05; For ACR20/50/70, SDAI, CDAI, DAS28-hsCRP and HAQ DI, there were numerical differences representing continuing improvement during the full 36 weeks of treatment (